


FIGURE 1



Universal V4.7A TA Instruments
Exo Up
Rev Heat Flow (W/g)
0.00
-0.01
-0.02
-0.03
-0.04
-0.05
-0.06
80
130
180
Temperature (°C)
135.64°C
140.39°C(I)
145.15°C

FIGURE 2



^{13}C-SSNMR of Compound I solid dispersion
^{19}F-ssNMR of Compound I solid dispersion

FIGURE 3



%T
320
300
280
260
240
220
200
180
160
140
120
100
80
60
40
20
0
3500
3000
2500
2000
1500
1000
500
cm-1

FIGURE 4



% Sofosbuvir Dissolved (% LS)
100
80
60
40
20
0
0
10
20
30
40
50
60
Time (minutes)
LOT 1
LOT 2
LOT 3
LOT 4
LOT 5

FIGURE 5



% Compound I Dissolved (% LS)
100
80
60
40
20
0
0
10
20
30
40
50
60
Time (minutes)
LOT 1
LOT 2
LOT 3
LOT 4
LOT 5

FIGURE 6



A
B
C
D
SOF + RBV
SOF + LDV + RBV
off treatment
off treatment
BL 2 4 6 8 10 12 2 4 8 12 24
Treatment week
Post-treatment week
1 2 3 4 5 6 7

FIGURE 7



A
SOF
% SOF Dissolved
Time (min)
Single Agent Control
Co-gran
Co-blend Bi-layer
B
LDV
% LDV Dissolved
Time (min)
Single Agent Control
Co-gran
Co-blend Bi-layer

FIGURE 8



Ledipasvir Solubility (mcg/mL)
100,000.00
10,000.00
1,000.00
100.00
10.00
1.00
0.10
0.01
0
1
2
3
4
5
6
7
8
pH
Measured, amorphous
Measured, D-tartrate
Measured, acetone solvate
Measured, crystalline FB Form III
Theoretical

FIGURE 9



Wk 0
Wk 8
Wk 12
COHORT 1
(n= 60)
Treatment naïve (non-cirrhotic)
1
SOF/LDV FDC
2
SOF/LDV FDC + RBV
3
SOF/LDV FDC
COHORT 2
(n= 40)
PI Failures (50% cirrhotic)
4
SOF/LDV FDC
5
SOF/LDV FDC + RBV

FIGURE 10



100%
80%
60%
40%
20%
19/20
21/21
18/19
18/19
21/21
RBV
–
+
–
–
+
Duration
8
8
12
12
12
Treatment naïve
(non-cirrhotic)
PI Failures
(50% Cirrhotic)

FIGURE 11